Handling Editor: Andrew Ewald
ABSTRACT
A lack of biological markers has limited our ability to identify the invasive cells responsible for glioblastoma multiforme (GBM). To become migratory and invasive, cells must downregulate matrix adhesions, which could be a physical marker of invasive potential. We engineered murine astrocytes with common GBM mutations, e.g. Ink4a (Ink) or PTEN deletion and expressing a constitutively active EGF receptor truncation (EGFRvIII), to elucidate their effect on adhesion. While loss of Ink or PTEN did not affect adhesion, counterparts expressing EGFRvIII were significantly less adhesive. EGFRvIII reduced focal adhesion size and number, and these cells – with more labile adhesions – displayed enhanced migration. Regulation appears to depend not on physical receptor association to integrins but, rather, on the activity of the receptor kinase, resulting in transcriptional integrin repression. Interestingly, EGFRvIII intrinsic signals can be propagated by cytokine crosstalk to cells expressing wild-type EGFR, resulting in reduced adhesion and enhanced migration. These data identify potential intrinsic and extrinsic mechanisms that gliomas use to invade surrounding parenchyma.
Footnotes
Competing interests
The authors declare no competing or financial interests.
Author contributions
Conceptualization: A.J.E., F.F.; Methodology: A.B., A.J.E., F.F.; Software: A.B.; Validation: A.B.; Formal analysis: A.B., P.B., A.D.P., B.Y., J.K.P.; Investigation: A.B., M.E., P.B., A.D.P., B.Y., J.K.P.; Resources: A.J.E., F.F.; Writing - original draft: A.B., A.J.E., F.F.; Writing - review & editing: A.B., A.J.E., F.F.; Supervision: A.J.E., F.F.; Project administration: A.J.E., F.F.; Funding acquisition: A.J.E., F.F.
Funding
Funding was provided by direct support from the Ludwig Institute for Cancer Research, National Institutes of Health (grant numbers: R01CA206880 and R21CA217735 to A.J.E., R01NS080939 to F.F., and R01NS116802 to A.J.E. and F.F.), the National Science Foundation (grant number: CMMI-1763139 to A.J.E.) and the National Science Foundation Graduate Research Fellowship program (to A.B.). Deposited in PMC for release after 12 months.
Supplementary information
Supplementary information available online at https://jcs.biologists.org/lookup/doi/10.1242/jcs.247189.supplemental
- Received April 3, 2020.
- Accepted November 9, 2020.
- © 2020. Published by The Company of Biologists Ltd
Log in using your username and password
Log in through your institution
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$30.00 .
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
Article navigation
Related articles
Cited by...
More in this TOC section
Similar articles
Subject collections
Other journals from The Company of Biologists
2020 at The Company of Biologists
Despite the challenges of 2020, we were able to bring a number of long-term projects and new ventures to fruition. While we look forward to a new year, join us as we reflect on the triumphs of the last 12 months.
Mole – The Corona Files
"This is not going to go away, 'like a miracle.' We have to do magic. And I know we can."
Mole continues to offer his wise words to researchers on how to manage during the COVID-19 pandemic.
Cell scientist to watch – Christine Faulkner
In an interview, Christine Faulkner talks about where her interest in plant science began, how she found the transition between Australia and the UK, and shares her thoughts on virtual conferences.
Read & Publish participation extends worldwide
“The clear advantages are rapid and efficient exposure and easy access to my article around the world. I believe it is great to have this publishing option in fast-growing fields in biomedical research.”
Dr Jaceques Behmoaras (Imperial College London) shares his experience of publishing Open Access as part of our growing Read & Publish initiative. We now have over 60 institutions in 12 countries taking part – find out more and view our full list of participating institutions.
JCS and COVID-19
For more information on measures Journal of Cell Science is taking to support the community during the COVID-19 pandemic, please see here.
If you have any questions or concerns, please do not hestiate to contact the Editorial Office.